Granzyme B Deficiency Exacerbates Lung Inflammation in Mice after Acute Lung Injury

• Published in: American journal of respiratory cell and molecular biology Vol. 49; no. 3; pp. 453 - 462
• Main Authors: Hirota, Jeremy A., Hiebert, Paul R., Gold, Matt, Wu, Dan, Graydon, Colin, Smith, Jane Ann, Ask, Kjetil, McNagny, Kelly, Granville, David J., Knight, Darryl A.
• Format: Journal Article
• Language: English
• Published: United States American Thoracic Society 01.09.2013
• Subjects: Acute Lung Injury - chemically induced; Acute Lung Injury - enzymology; Acute Lung Injury - immunology; Acute Lung Injury - mortality; Administration, Intranasal; Animals; Antigens, CD - genetics; Antigens, CD - immunology; Bleomycin; Case-Control Studies; Forkhead Transcription Factors - genetics; Forkhead Transcription Factors - immunology; Gene Expression; Granzymes - deficiency; Granzymes - genetics; Granzymes - immunology; Humans; Killer Cells, Natural - enzymology; Killer Cells, Natural - immunology; Killer Cells, Natural - pathology; Lung - enzymology; Lung - immunology; Lung - pathology; Mice; Mice, Knockout; Pneumonia - chemically induced; Pneumonia - enzymology; Pneumonia - immunology; Pneumonia - mortality; Respiratory Distress Syndrome, Adult - enzymology; Respiratory Distress Syndrome, Adult - genetics; Respiratory Distress Syndrome, Adult - immunology; Respiratory Distress Syndrome, Adult - pathology; Survival Analysis; T-Lymphocytes, Regulatory - enzymology; T-Lymphocytes, Regulatory - immunology; T-Lymphocytes, Regulatory - pathology
• ISSN: 1044-1549; 1535-4989; 1535-4989
• DOI: 10.1165/rcmb.2012-0512OC

Granzyme B (GzmB) is a serine protease with intracellular and extracellular activities capable of regulating inflammation through cytokine processing and the apoptosis of effector cells. We tested the hypothesis that GzmB expression in T regulatory cells (Tregs) is required for the control of inflammatory responses and pathology during acute lung injury. To substantiate the clinical relevance of GzmB during lung injury, we performed GzmB immunohistochemistry on lung tissue from patients with acute respiratory distress syndrome (ARDS) and healthy control subjects. We also performed in vivo experiments with wild-type (WT) C57BL/6 and GzmB(-/-) mice exposed to a single intranasal instillation of bleomycin to model lung injury. Our results demonstrate that the expression of GzmB was elevated in ARDS lung sections, relative to healthy control samples. Bleomycin-exposed GzmB(-/-) mice exhibited greater morbidity and mortality, which was associated with increased numbers of lung lymphocytes. Bleomycin induced an equal increase in CD4(+)/CD25(+)/FoxP3(+) Treg populations in WT and GzmB(-/-) mice. GzmB expression was not significant in Tregs, with the majority of the expression localized to natural killer (NK)-1.1(+) cells. The expression of GzmB in NK cells of bleomycin-exposed WT mice was associated with greater lymphocyte apoptosis, reduced total lymphocyte numbers, and reduced pathology relative to GzmB(-/-) mice. Our data demonstrate that GzmB deficiency results in the exacerbation of lymphocytic inflammation during bleomycin-induced acute lung injury, which is associated with pathology, morbidity, and mortality.